Pfizer has been downgraded from Buy to Hold following a roughly 20% total return since last October. The analyst notes that the stock's valuation, currently around 8.7 times EV/EBITDA, offers less downside protection, and near-term earnings visibility remains uncertain. While 2026 revenue guidance of $61.5 billion and new product launches are positive, challenges such as softness in Vyndaqel sales and Medicaid pricing changes cloud the short-term outlook. Existing investors may hold for the 6.2% dividend yield, but new buyers are advised to wait for clearer valuation or catalyst improvements.
Pfizer trades at USD 27.71 on Pluang as of Sep 22, 2026, with a slight 0.11% drop in one day. The stock's dividend yield remains attractive at 6.2%, supporting existing investors. Market activity is balanced with 49% selling and 51% buying, reflecting cautious sentiment amid valuation concerns.
Pfizer reported a strong quarterly performance, raising its revenue guidance to $61.5 billion driven by a robust non-COVID product portfolio and recent acquisitions. The company is implementing operational efficiency programs aimed at saving $9.7 bil...
Pfizer remains an attractive income stock, yielding 6.22% and trading at 9.3 times the 2026 expected earnings per share. Its non-COVID business is growing operationally by 5%, supported by a strong pipeline and $1.5 billion ahead of its 2026 business...
Pfizer has paused its annual dividend increase for the first time in over a decade, maintaining a quarterly payout of $0.43 throughout 2026. This pause comes despite a strong 6.2% dividend yield and solid adjusted earnings coverage, reflecting cautio...
